Post-IPO Equity - CNS Pharmaceutical
Investment Firm
Overview
CNS Pharmaceutical is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors.
Announced Date
Jun 14, 2024
Funding Type
Post Ipo Equity
Highlights
Location
United States, North America
Social
Investor Lead
N/A
Participant Investors
1
No investment info available on this profile
Round Details and Background
CNS Pharmaceutical raised $1370000 on 2024-06-14 in Post-IPO Equity
CNS Pharmaceutical is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors.
Company Funding History
4
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jan 10, 2022 |  Post-IPO Equity - CNS Pharmaceutical | - | 11.5M | |
| Nov 30, 2022 | Post-IPO Equity - CNS Pharmaceutical | - | 6.0M | |
| Jan 29, 2024 | Post-IPO Equity - CNS Pharmaceutical | - | 4.0M | |
| Jun 14, 2024 | Post-IPO Equity - CNS Pharmaceutical | - | 1.4M |
Recent Activity
News
Jun 14, 2024
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
News
Jun 14, 2024
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
News
Jun 14, 2024
Yahoo Finance - CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement